Abstract

. TB is an important infection worldwide and its incidence is increasing in the U. S. In view of this, much interest has been directed to the development of novel drugs or delivery systems that are effective against the infection to improve patient survival. This application deals with the development of microencapsulated anti-TB drugs with the hope of accomplishing the aforementioned goal. Once developed, these drugs will be tested in vitro, using a murine macrophage cell line and a human monocytic cell line. Afterwards, the drugs will be tested in mice infected with MTB.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI038185-01A1
Application #
2075134
Study Section
AIDS and Related Research Study Section 5 (ARRE)
Project Start
1995-08-01
Project End
1999-07-31
Budget Start
1995-08-01
Budget End
1996-07-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205

  Publications

Barrow, Esther L W; Barrow, William W; Quenelle, Debra C et al. (2007) Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice. Drug Deliv 14:119-27
Barrow, William W (2004) Microsphere technology for chemotherapy of mycobacterial infections. Curr Pharm Des 10:3275-84
Barrow, W W (2001) Treatment of mycobacterial infections. Rev Sci Tech 20:55-70
Quenelle, D C; Winchester, G A; Staas, J K et al. (2001) Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. Antimicrob Agents Chemother 45:1637-44
Quenelle, D C; Staas, J K; Winchester, G A et al. (1999) Efficacy of microencapsulated rifampin in Mycobacterium tuberculosis-infected mice. Antimicrob Agents Chemother 43:1144-51
Barrow, E L; Winchester, G A; Staas, J K et al. (1998) Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother 42:2682-9
Wright, E L; Quenelle, D C; Suling, W J et al. (1996) Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob Agents Chemother 40:2206-8